MedTrace Logo

Postoperative Chemotherapy in High-Grade Appendiceal Adenocarcinoma With Peritoneal Carcinomatosis

NCT02420509 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 2

Last updated 2025-06-04

No results posted yet for this study

Summary

The purpose of this study is to find out if postoperative chemotherapy in patients with high-grade appendix cancer after surgery improves outcomes.

The postoperative chemotherapy will consist of 5-FU (with leucovorin) or capecitabine with bevacizumab. These drugs are approved for use in people with colon cancer, and they are used at UCSD for some patients with appendix cancer.

The purpose of this study is to explore the safety and efficacy of the postoperative chemotherapy treatment on cancer.

Conditions

Interventions

DRUG

systemic chemotherapy

twelve months of 5-FU or capecitabine with bevacizumab starting 4-8 weeks after surgery

Sponsors & Collaborators

Principal Investigators

  • Joel M Baumgartner, MD, MAS · University of California, San Diego

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-08-27
Primary Completion
2017-02-09
Completion
2019-04-02

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02420509 on ClinicalTrials.gov